

Original Research

Association of Short-Term Pollen Exposure With Lung Function in COPD Patients

James P. Healy, MPH¹ Wenli Ni, PhD^{1,2,3} Brent Coull, PhD⁴ Petros Koutrakis, PhD³ Andrew Synn, MD²
Nicholas Nassikas, MD^{1,2} Mary B. Rice, MD, MPH^{1,2,3}

Abstract

Background: Environmental exposures such as air pollution are well established triggers for chronic obstructive pulmonary disease (COPD) exacerbation and impaired lung function. However, the role of aeroallergens, particularly pollen, has not been thoroughly examined in COPD, despite evidence that pollen inhalation can cause airway inflammation. We investigated whether short-term exposure to higher concentrations of ambient pollen is associated with changes in lung function in people with COPD.

Methods: Thirty COPD participants, contributing 1808 observations, were enrolled in the Study of Pollution and COPD Exacerbation and completed 4 clinic visits over one year while performing daily spirometry during four 30-day seasonal periods. Ambient total pollen was measured regionally. Associations of short-term pollen exposure (lag 1–7 days and cumulative 3- and 7-day concentrations) with forced expiratory volume in 1 second (FEV₁) and forced vital capacity were assessed using distributed lag nonlinear models with a generalized additive mixed model. We tested if inflammatory biomarkers, inhaler medications, asthma history, and concurrent exposure ambient pollutants (nitrogen oxide, particulate matter diameter of 2.5 micrometers or less, ozone) modified associations between pollen exposure and lung function.

Results: Pollen exposure at lag 3 day was associated with a lower FEV₁ (–5.5mL per interquartile range pollen increase; 95% confidence interval [CI]: –9.6, –1.3). Cumulative 3-day pollen exposure was similarly associated with a lower FEV₁ (–4.9mL; 95% CI: –9.6, –0.2). Associations of pollen and FEV₁ were greater in those with higher C-reactive protein and a diagnosis of asthma.

Conclusions: In this longitudinal study of people with COPD, higher short-term exposure to ambient pollen in the preceding 3 days was associated with a lower FEV₁. Our findings suggest that aeroallergen exposure may worsen airflow obstruction in people with COPD.

1. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2. Center for Climate, Health, and the Global Environment, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
3. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States

Abbreviations:

BMI=body mass index; **CI**=confidence interval; **COPD**=chronic obstructive pulmonary disease; **CRP**=C-reactive protein; **CVD**=cardiovascular disease; **DLNM**=distributed lag nonlinear models; **FEV₁**=forced expiratory volume in 1 second; **FVC**=forced vital capacity; **GAMM**=generalized additive mixed model; **GED**=general education development; **GOLD**=Global initiative for chronic Obstructive Lung Disease; **ICS**=inhaled corticosteroid; **IQR**=interquartile range; **NO₂**=nitrogen dioxide; **O₃**=ozone; **PM_{2.5}**=particulate matter diameter of 2.5 micrometers or less; **SD**=standard deviation; **SPACE**=Study of Air Pollution and COPD Exacerbation

Funding Support:

None

Citation:

Healy JP, Ni Wenli, Coull B, et al. Association of short-term pollen exposure with lung function in COPD patients. *Chronic Obstr Pulm Dis.* 2026;13(4):284-292. doi: <https://doi.org/10.15326/jcopdf.2025.0735>

Publication Dates:

Date of Acceptance: April 23, 2026

Published Online Date: May 9, 2026

Address correspondence to:

Mary B. Rice
Harvard T.H. Chan School of Public Health
665 Huntington Ave
Boston, MA 02115
Email: mbrice@hsph.harvard.edu

Keywords:

COPD; lung function; pollen; nitrogen dioxide

This article has an online supplement.

Introduction

Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease that is characterized by progressive persistent airflow limitation and recurring exacerbations. Over 390 million individuals are affected by COPD globally,¹ and it is the third leading cause of death worldwide.² COPD cases and related exacerbations are predicted to rise due to an aging global population and worsening climatic and environmental conditions.^{3,4} Acute exacerbations from various factors such as infections, air pollutants, and environmental triggers can rapidly worsen lung function and contribute to morbidity, hospitalization, and even mortality.^{5,6} Previous studies, including our own work in the Study of Pollution and COPD Exacerbation (SPACE) study, have found that exposure to air pollutants is associated with a lower forced expiratory volume in 1 second (FEV₁), worse respiratory symptoms, and increased health care reliance in COPD sufferers.⁷⁻¹¹ While the impact of air pollution on COPD is well-studied, less is understood about the effect of aeroallergens on the respiratory health of people with COPD.

Most research on the respiratory effect of pollen exposure has concentrated on allergic rhinitis or asthma. Pollen is a known trigger of airway inflammation, bronchoconstriction, and symptom exacerbation in allergic asthma.^{12,13} However, a notable proportion of COPD patients exhibit allergic sensitization or atopy, with studies indicating that COPD patients who are sensitized to environmental allergens may experience more frequent symptoms and poorer lung function.^{14,15} Mechanistically, pollen exposure can induce neutrophilic and eosinophilic inflammation, mucous hypersecretion, and increased airway reactivity, processes that could worsen airflow obstruction in COPD.^{10,16} Further, pollen is an increasingly important exposure in the context of climate change, with higher temperatures and variable precipitation leading to extended pollen seasons, higher concentrations within the season, and more potent allergenic particles, elevating population-level respiratory risk.¹⁷⁻²⁰ As previous ecological studies have linked aeroallergen exposure to increased COPD hospitalizations,²¹ and a time-series analysis in Beijing showed associations between ambient pollen and COPD-related clinical visits.²² However, few studies have examined objective lung function as a measure of airway response to pollen exposure in COPD.

To address this gap, we investigated the association between short-term pollen exposure over the preceding days and differences in FEV₁ and forced vital capacity (FVC) among former smokers with moderate-to severe COPD.

Methods

Study Population

The study population comprised 30 participants diagnosed with COPD who were former smokers.

These participants were recruited as part of SPACE, conducted at the Beth Israel Deaconess Medical Center in Boston, Massachusetts.^{11,23} Eligibility criteria for participation included a clinical diagnosis of COPD, former smoking status with at least 6 months smoke-free, and moderate airflow obstruction. Specifically, participants required an FEV₁/FVC ratio <0.70 and an FEV₁ between 50% and 80% of the predicted value, consistent with Global initiative for chronic Obstructive Lung Disease (GOLD)²⁴ Stage 2. A distinctive eligibility requirement was that participants' home addresses be within 50km of the Harvard Supersite air pollution monitor at Harvard Medical School. The study was approved by the Committee on Clinical Investigations at Beth Israel Deaconess Medical Center.

Data Collection

Data collection for the study spanned from February 24, 2017 to January 17, 2019. Upon entry into the study, comprehensive baseline information was collected for each participant, including demographic details, height, weight, past medical history, and initial measures of lung function. Participants were subsequently observed for up to 4 nonconsecutive 30-day periods, distributed across 4 different seasons over a 12-month duration.

Exposure Assessment

Total pollen count was obtained as a regional daily average from Asthma and Allergy Affiliates, Inc., based in Salem, Massachusetts. A Rotorod sampler was used to record daily pollen concentrations, measured in grains per cubic meter (grains/m³). Total pollen included tree, grass, and weed pollen, along with "other" or unclassified pollen particles.²⁵ Our measured pollen season was defined as March through October, coinciding with the pollen season in the Northeastern United States. Observations outside the pollen season were excluded. Pollen collected over weekends and holidays was counted on the following weekday; therefore, weekend and holiday values reflect the pollen concentrations averaged across the days of collection (e.g., Saturday, Sunday, and Monday pollen concentrations are the average across those 3 days). Moving averages are defined as the average exposure over the period of days preceding the lung function measurement (e.g., a 3-day moving average is the sum of pollen over 3 days divided by 3). Temperature was defined as the daily mean temperature. Daily ambient air pollution data were obtained from state-owned stationary monitors in the Boston area. For particulate matter diameter

of 2.5 micrometers or less (PM_{2.5}) and nitrogen dioxide (NO₂), we averaged daily concentrations from multiple Boston monitors; for ozone (O₃), we used data from the Boston (Roxbury neighborhood) state monitor as previously described.¹¹

Outcome Assessment

Participants performed daily lung function measurements each morning, prior to taking any medications or inhalers, utilizing a portable EasyOne™ Plus Diagnostic Spirometer (nidd Medical Technologies; Andover, Massachusetts). This device meets the guidelines established by the American Thoracic Society and incorporates built-in quality assurance and incentive software to ensure data reliability. By the conclusion of the follow-up period, the 30 participants collectively contributed a total of 1808 observations during the pollen season (March to October).

Statistical Analysis

To assess the relationship between short-term total pollen exposure at lag 1 to 7 days and lung function in COPD, as well as the cumulative association over lag 1–3 days, we used distributed lag nonlinear models (DLNM) combined with a generalized additive mixed model (GAMM). We adjusted for potential confounders including age, sex, height, weight, education, seasonality (sine and cosine terms of date), and 3-day moving averages of temperature (lag 1–3 days) prior to the spirometry assessment.

We assessed potential effect modification by markers of type 2 inflammation (blood absolute eosinophils ≥ 150 versus < 150 cells/ μ L), systemic inflammation (C-reactive protein [CRP] > 3 versus ≤ 3 mg/L), history of cardiovascular disease (CVD), history of asthma, and baseline use of maintenance medications (inhaled corticosteroids [ICSs], long-acting beta₂-agonists, long-acting muscarinic antagonists, and beta-blockers). Moreover, we assessed effect modification by ambient air pollutants (PM_{2.5}, NO₂, and O₃), categorized as high versus low based on the median 3-day moving average of each pollutant prior to the spirometry assessment. Differences in the estimated effects between subgroup strata were formally evaluated for statistical significance using a Z-test.

Sensitivity analyses were performed by adding other environmental exposures (humidity, NO₂, O₃, and PM_{2.5}) to the primary model. Additionally, we performed sensitivity analyses: excluding Sundays through Tuesdays to account for weekend/holiday pollen averaging; and removing all covariates from our model. All analyses were conducted in R version 4.3.1.

Results

Study Population and Exposure

In this longitudinal study, we included 30 COPD participants with 1808 observations. Table 1 summarizes baseline population characteristics. Participants had a mean age of 71.1 years (standard deviation 8.4), those as female from birth were the majority (53.3%), were predominantly White (82%), and most had at least some postsecondary education. Across all study visits, the mean FEV₁ was 1.3L, and FVC was 2.6L. The average within-participant variation was 0.13L for FEV₁ and 0.24L for FVC. Table 2 outlines the distribution of exposures encountered by the study participants. Median exposure to pollen was 32.4 grains/m³ with an interquartile range (IQR) of 145.4 grains/m³ (Supplemental Table 1 in the online supplement).

Pollen Exposure and Lung Function Associations

We observed an association between higher total pollen exposure at lag 3-day and lower FEV₁ (Figure 1). Each IQR (145.4 grains/m³) difference in total pollen exposure was associated with a 5.5mL lower FEV₁ (95% confidence interval [CI]: -9.6, -1.3). There was a cumulative association between higher total pollen exposure at lag 1–3 days with a lower FEV₁ of 4.9mL (95% CI: -9.6, -0.2). There was a similar pattern but nonsignificant cumulative association between higher total pollen exposure at lag 1–3 days and lower FVC of 7.9 (-15.9, 0.1) (Supplemental Table 2 in the online supplement). For the subtypes of pollen, we observed a negative pattern between higher tree and other pollen exposure at a 7-day lag and lower FEV₁, although this association did not reach statistical significance, nor did we see similar negative patterns at Lag 1 or 3 days (Supplemental Table 3 in the online supplement).

Effect Modification

We observed that the association between total pollen exposure at lag 3 day and lower FEV₁ was more pronounced among individuals with elevated baseline systemic inflammation (CRP > 3 mg/L) and a history of asthma (Figure 2, *P*-interactive < 0.05 for both tests of effect modification). Similarly, the use of maintenance inhaled therapies (ICSs) appeared to slightly attenuate the association between pollen and lower FEV₁ compared to nonuse, but this modifying effect was not statistically significant (*P*-interactive: 0.15). Furthermore, the negative association between pollen and FEV₁ appeared slightly more pronounced on days characterized by high ambient NO₂ exposure compared to low NO₂ days, although this difference was not significant (*P*-interactive: 0.11). We found no evidence of interactive effects regarding eosinophils, CVD, other inhalers, and concurrent exposure to other ambient air pollutants (PM_{2.5} and O₃) on FEV₁.

Table 1. Baseline Characteristics of Study Participants^a

Characteristic	Mean±SD or No. (%)
Age, years	71.11 (7.98)
BMI, kg/m ²	31.84 (7.10)
Sex, n (%)	
Male	13 (43.3)
Female	17 (56.7)
Race, n (%)	
Black, Non-Hispanic	5 (18.0)
White, Non-Hispanic	25 (82.0)
Education, n (%)	
Up to Grade 12 or GED	8 (26.7)
Some College/Associate's Degree	13 (43.3)
Bachelor's or Above	9 (30.0)
Baseline Lung Function	
FEV ₁ , L	1.17 (0.55)
FVC, L	2.39 (0.85)
History of Asthma, n (%)	
Yes	15 (51.7)
No	14 (48.3)
Cardiopulmonary Comorbidities (CVD), n (%)	
Yes	11 (36.7)
No	19 (63.3)
Type 2 Inflammation (Blood Eosinophils), n (%)	
≥150 cells/μL	12 (60.0)
<150 cells/μL	8 (40.0)
Systemic Inflammation (CRP), n (%)	
>3 mg/L	12 (63.2)
≤3 mg/L	7 (36.8)
Inhaled Corticosteroids, n (%)	
Yes	18 (60.0)
No	12 (40.0)
Long-Acting Beta2-Agonists, n (%)	
Yes	21 (70.0)
No	9 (30.0)
Long-Acting Muscarinic Antagonists, n (%)	
Yes	16 (53.3)
No	14 (46.7)
Beta-Blockers, n (%)	
Yes	7 (23.3)
No	23 (76.7)


^aN=30SD=standard deviation; BMI=body mass index; GED=general education development; FEV₁=forced expiratory volume in 1 second; FVC=forced vital capacity; CVD=cardiovascular disease; CRP=C-reactive protein**Table 2. Exposure Descriptive Statistics**

Exposure Variable	# of Observations	Median	IQR
Total Pollen (1–3 day avg, grains/m ³)	1808	32.4	145.4
Temperature (1–3 day avg, °C)	1808	12.7	15.4
NO₂ (1–3 day avg, ppb)	1808	7.3	3.7
Humidity (1–3 day avg, %)	1808	65.9	16.4

(n=1808 observations)

IQR=interquartile range; NO₂=nitrogen dioxide

Figure 1. Difference in Forced Expiratory Volume in 1 Second (mL) Associated With Interquartile Range Increase in Total Pollen (95% Confidence Interval)



The estimated difference in FEV₁ (mL) associated with an IQR increase in total ambient pollen. Estimates were generated using GAMMs incorporating a DLNM with linear function. All models were adjusted for baseline age, gender, height, weight, education level, seasonality, and ambient temperature, with random intercepts for participant ID nested within sequence number. Central points represent the estimated difference in FEV₁ (mL), and horizontal error bars represent the 95% CI.

FEV₁=forced expiratory volume in 1 second; CI=confidence interval; IQR=interquartile range; GAMMs=generalized additive mixed model; DLNM=distributed lag nonlinear models

For FVC the patterns of effect modification were similar to FEV₁. However, no tests of effect modification were statistically significant, except for NO₂ exposure. We found a stronger negative association with pollen exposure and FVC on days characterized by high concurrent ambient NO₂ (-19.1mL; 95% CI: -30.9 to -7.3) compared to low NO₂ exposure (-0.8mL; 95% CI: -12.4 to 10.8) per IQR increased in pollen (*P*-interaction<0.05).

Sensitivity Analyses


The cumulative association between pollen exposure at lag 1–3 days and FEV₁ remained robust across multiple sensitivity analyses (Supplemental Table 4 in the online supplement). Upon adjusting for humidity, NO₂, O₃, and PM_{2.5}, a significant negative association between total pollen and FEV₁ was still observed. Our results also remained robust upon removing all covariates from our distributive model. Further, we performed a sensitivity analysis excluding Sundays through Tuesdays to account for weekend/holiday pollen averaging. We found that the direction and effect size of FEV₁ (cumulative associations with lag 1–3 days) remained similar (-4.6 mL 95% CI: -10.6 mL, 1.3 mL).

Discussion

In this longitudinal study of 30 COPD patients with 1808 observations, we found that higher short-term pollen exposure was associated with a lower FEV₁. Short-term exposure to pollen at lag 3 days was associated with a 5.5mL lower FEV₁, and the cumulative lag 1-3 day association yielded a similar effect size. This finding suggests that pollen may impair expiratory airflow in patients with COPD, with a possible cumulative effect that takes more than a day to develop.

While we found associations of pollen and lung function in our study of COPD patients overall, associations predominated among those with asthma-COPD overlap. Studies in asthmatic populations demonstrate that pollen can increase bronchial hyperresponsiveness in individuals, not classically "allergic."^{10,22,26} Our results are consistent with such past asthma literature, especially that of Erbas et al whose meta-analysis showed that acute pollen exposure is associated with reduced lung function and increased hospitalizations for emergency presentations due to asthma exacerbations.¹⁷ Previous evidence has also suggested that nonasthmatic people are susceptible to airway inflammation and respiratory effects of pollen exposure. A study of acute pollen exposure and respiratory hospital admissions found

Figure 2. Association Between Lag 3-Day Pollen Exposure and Forced Expiratory Volume in 1 Second by C-Reactive Protein Level, Comorbid Asthma, Inhaled Corticosteroid Use, and Ambient Nitrogen Dioxide



The estimated cumulative difference in FEV₁ (mL) associated with an IQR increase in total ambient pollen at lag 3 day. Estimates were generated using GAMMs incorporating a DLNM with linear function. All models were adjusted for baseline age, gender, height, weight, education level, seasonality, and ambient temperature, with random intercepts for participant ID nested within sequence number. Central points represent the estimated difference in FEV₁ (mL), and horizontal error bars represent the 95% CI. Red coloring indicates a statistically significant difference between the subgroup strata (P-interaction < 0.05).

CRP=C-reactive protein; ICS=inhaled corticosteroid; NO₂=nitrogen dioxide; FEV₁=forced expiratory volume in 1 second; IQR=interquartile range; GAMMs=generalized additive mixed model; DLNM=distributed lag nonlinear models; CI=confidence interval

an association with COPD patients but not people with asthma.¹⁸

Throughout this study, we saw that the association of pollen on lower FEV₁ appeared at lag 3 but not lag 1. This is consistent with asthma and atopy studies showing delayed airway responses to pollen. For example, Idroze et al found that grass pollen exposure was associated with airway obstruction 2–3 days after exposure in a cohort with atopy.²⁷ Further, grass pollen was shown to have a lagged inflammatory response suggesting that pollen related inflammation may peak after a short lag.²⁸

We saw that the association between pollen and lower FEV₁ was modified by elevated systemic inflammation (CRP)

and history of asthma. Systemic inflammation measures such as CRP have been found to be raised in COPD patients and demonstrate an inverse correlation with FEV₁.^{29,30} It is, therefore, plausible that higher CRP could modify and even exacerbate the pollen-reduced FEV₁ relationship through augmented inflammatory pathways. While not statistically significant, we found that those who used steroid inhalers had a less pronounced association between pollen and FEV₁, suggesting that palliation of inflammatory pathways in the airways may help prevent some of these effects.

We also explored potential modification by air pollutants, as prior studies have found that pollutants can synergistically enhance allergenicity and respiratory effects

of pollen.³¹⁻³³ We observed that the negative association between pollen and FVC was more pronounced on high-NO₂ days for FVC with a similar pattern for FEV₁. Previous experimental studies have shown that traffic-related air pollution can enhance the allergenic potency of pollen through nitration, synergistic oxidative stress, fragmentation, or a combination of all previously mentioned.^{31,34} Further, studies of diesel adjuvants have also shown that exhaust particles can increase immunoglobulin E production and airway inflammation upon allergen co-exposure.^{31,35} These findings indicate that individuals in urban residences with a multiple exposure profile of aeroallergens and pollutants may face compounded respiratory risks.

The study's strengths include its longitudinal design with daily repeated spirometry using standardized home equipment. Further, the daily regional data on temperature and air pollutants allowed us to control environmental confounders. However, this study has limitations worth acknowledging. Despite multiple daily lung function measurements, the modest sample size of only 30 individuals limits statistical power and generalizability. Our use of a single regional pollen monitor may have introduced some exposure misclassification,³⁶ although pollen levels tend to be consistent across urban environments.³⁷ Further, exposure error may be related to the averaging of weekend values. While Sunday to Tuesday sensitivity tests showed no change in direction or effect size, such averaging may have introduced noise. Clinically, the low magnitude of FEV₁ changes observed may be of limited concern in well managed patients but could become more consequential in those with advanced COPD with severely impaired lung function or multitrigger exacerbations. Finally, our reliance on a single regional monitoring station to estimate ambient pollen exposure may introduce spatial exposure misclassification. High-resolution spatiotemporal pollen models (e.g., 3km by 3km grids) were unfortunately not available for our specific study period (2017–2019). Importantly, however, our analysis focuses on acute, short-term health effects, which rely on day-to-day temporal variations in exposure rather than long-term spatial differences. Therefore, a central monitor may adequately capture the day-to-day temporal exposure variability required to assess acute respiratory effects.

Our findings have significance in the context of climate change. Pollen seasons are lengthening and pollen concentrations are higher as a result of climate change.^{7,8,19,20} For people with COPD and asthma-COPD overlap whose lung function is already impaired, any further obstruction or inflammation caused by pollen exposure could have clinical consequences. Patients with COPD may benefit from awareness of potential aeroallergen risks, particularly during high-pollen days and high pollen days in combination with urban air pollution. For individual patients, preventive interventions such as indoor air filtration

and possible pharmacological therapies may be beneficial.³⁸

Conclusion

Short-term increases in ambient pollen exposure were associated with lower FEV₁ among COPD patients. As pollen seasons are lengthening and levels are increasing due to climate change, greater attention to the respiratory effects of pollen on COPD and the evaluation of potential prevention strategies are warranted.

Acknowledgements

Author contributions:

Declaration of Interest

References

1. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR Respiratory Global Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic respiratory diseases (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447-458. [https://doi.org/10.1016/S2213-2600\(21\)00511-7](https://doi.org/10.1016/S2213-2600(21)00511-7)

2. Wang Y, Han R, Ding X, Feng W, Gao R, Ma A. Chronic obstructive pulmonary disease across three decades: trends, inequalities, and projections from the Global Burden of Disease Study 2021. *Front Med (Lausanne)*. 2025;12:1564878. <https://doi.org/10.3389/fmed.2025.1564878>

3. Salvi S. Health effects of ambient air pollution in children. *Paediatr Respir Rev*. 2007;8(4):275-280. <https://doi.org/10.1016/j.prrv.2007.08.008>

4. DeVries R, Kriebel D, Sama S. Outdoor air pollution and COPD-related emergency department visits, hospital admissions, and mortality: a meta-analysis. *COPD*. 2017;14(1):113-121. <https://doi.org/10.1080/15412555.2016.1216956>

5. Hansel NN, McCormack MC, Kim V. The effects of air pollution and temperature on COPD. *COPD*. 2016;13(3):372-379. <https://doi.org/10.3109/15412555.2015.1089846>

6. D'Amato G, Cecchi L, D'Amato M, Annesi-Maesano I. Climate change and respiratory diseases. *Eur Respir Rev*. 2014;23(132):161-169. <https://doi.org/10.1183/09059180.00001714>

7. Lake IR, Jones NR, Agnew M, et al. Climate change and future pollen allergy in Europe [Published erratum appears in: *Environ Health Perspect*. 2018;126(7):079002]. *Environ Health Perspect*. 2017;125(3):385-391. doi: <https://doi.org/10.1289/EHP173>.

8. Bielory L, Lyons K, Goldberg R. Climate change and allergic disease. *Curr Allergy Asthma Rep*. 2012;12:485-494. <https://doi.org/10.1007/s11882-012-0314-z>

9. World Health Organization (WHO). Global Health Estimates: Chronic obstructive pulmonary disease (COPD). WHO website. Published 2023. Accessed December 2025. <https://www.who.int/data/global-health-estimates>

10. Nurhussain L, Kang C, Koutrakis P, Coull BA, Rice MB. Air pollution exposure and daily lung function in chronic obstructive pulmonary disease: effect modification by eosinophilia. *Ann Am Thorac Soc*. 2022;19(5):728-736. <https://doi.org/10.1513/AnnalsATS.202107-846OC>

11. Aglan A, Synn AJ, Nurhussien L, et al. Personal and community-level exposure to air pollution and daily changes in respiratory symptoms and oxygen saturation among adults with COPD. *Hyg Environ Health Adv*. 2023;6:100052. <https://doi.org/10.1016/j.heha.2023.100052>

12. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2023 update. GINA website. Published 2023. Accessed December 2025. <https://ginasthma.org/wp-content/uploads/2024/05/GINA-2023-Report-WMSA.pdf>

13. Darrow LA, Hess J, Rogers CA, Tolbert PE, Klein M, Sarnat SE. Ambient pollen concentrations and emergency department visits for asthma and wheeze. *J Allergy Clin Immunol*. 2012;130(3):630-638.e4. <https://doi.org/10.1016/j.jaci.2012.06.020>

14. Sapey E, Stockley RA. COPD exacerbations 2: aetiology. *Thorax*. 2006;61(3):250-258. <https://doi.org/10.1136/thx.2005.041822>

15. Zhang J, Wei Y, Fang Z. Ozone pollution: a major health hazard worldwide. *Front Immunol*. 2019;10:2518. <https://doi.org/10.3389/fimmu.2019.02518>

16. Behrendt H, Becker WM. Localization, release and bioavailability of pollen allergens: the influence of environmental factors. *Curr Opin Immunol*. 2001;13(6):709-715. [https://doi.org/10.1016/S0952-7915\(01\)00283-7](https://doi.org/10.1016/S0952-7915(01)00283-7)

17. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger of child and adolescent asthma emergency department presentations: a systematic review and meta-analysis. *Allergy*. 2018;73(8):1632-1641. <https://doi.org/10.1111/all.13407>

18. Hanigan IC, Johnston FH. Respiratory hospital admissions were associated with ambient airborne pollen in Darwin, Australia, 2004-2005. *Clin Exp Allergy*. 2007;37(10):1556-1565. <https://doi.org/10.1111/j.1365-2222.2007.02800.x>

19. World Health Organization, Institutional Repository for Information Sharing (WHO, IRIS). Climate change, air pollution, pollen and health: technical brief. WHO, IRIS website. Published 2025. Accessed December 2025. <https://doi.org/10.2471/B09412>

20. Zhang Y, Steiner AL. Projected climate-driven changes in pollen emission season length and magnitude over the continental United States. *Nat Commun*. 2022;13:1234. <https://doi.org/10.1038/s41467-022-28764-0>

21. Jamieson DB, Matsui EC, Belli A, et al. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2013;188(2):187-192. <https://doi.org/10.1164/rccm.201211-2103OC>

22. Liu A, Sheng W, Tang X. Atmospheric pollen concentrations and chronic obstructive pulmonary disease (COPD) patient visits in Beijing: a time-series analysis using a generalized additive model. *Sci Rep*. 2024;14:3462. <https://doi.org/10.1038/s41598-024-54055-3>

23. Sun WY, Zhang C, Synn AJ, Nurhussien L, Coull BA, Rice MB. Change in inhaler use, lung function, and oxygenation in association with symptoms in COPD. *Chronic Obstr Pulm Dis*. 2020;7(4):404-412. <https://doi.org/10.15326/jcopdf.7.4.2020.0138>

24. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO GOLD workshop summary. *Am J Respir Crit Care Med*. 2001;163(5):1256-1276. <https://doi.org/10.1164/ajrccm.163.5.2101039>

25. Nassikas NJ, Luttmann-Gibson H, Rifas-Shiman SL, Oken E, Gold DR, Rice MB. Acute exposure to pollen and airway inflammation in adolescents. *Pediatr Pulmonol.* 2024;59(5):1313-1320. <https://doi.org/10.1002/ppul.26908>
26. Erbas B, Chang JH, Dharmage S, et al. Do levels of airborne grass pollen influence asthma hospital admissions? *Clin Exp Allergy.* 2007;37(11):1641-1647. <https://doi.org/10.1111/j.1365-2222.2007.02818.x>
27. Idrose NS, Tham RCA, Lodge CJ, et al. Is short-term exposure to grass pollen adversely associated with lung function and airway inflammation in the community? *Allergy.* 2021;76(4):1136-1146. <https://doi.org/10.1111/all.14566>
28. Roberts G, Hurley C, Bush A, Lack G. Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. *Thorax.* 2004;59(9):752-756. <https://doi.org/10.1136/thx.2003.008722>
29. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. *Chest.* 2008;133(6):1336-1343. <https://doi.org/10.1378/chest.07-2433>
30. Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. *Caspian J Intern Med.* 2012;3(2):428-435. <https://pubmed.ncbi.nlm.nih.gov/articles/PMC3861908/>
31. Reinmuth-Selzle K, Kampf CJ, Lucas K, et al. Air pollution and climate change effects on allergies in the Anthropocene: abundance, interaction and modification of allergens and adjuvants. *Environ Sci Technol.* 2017;51(8):4119-4141. <https://doi.org/10.1021/acs.est.6b04908>
32. Lam HCY, Jarvis D, Fuertes E. Interactive effects of allergens and air pollution on respiratory health: a systematic review. *Sci Total Environ.* 2021;757:143924. <https://doi.org/10.1016/j.scitotenv.2020.143924>
33. Beggs PJ. Impacts of climate change on aeroallergens: past and future. *Clin Exp Allergy.* 2004;34(10):1507-1513. <https://doi.org/10.1111/j.1365-2222.2004.02061.x>
34. Franze T, Weller MG, Niesser R, Poschl U. Protein nitration by polluted air. *Environ Sci Technol.* 2005;39(6):1673-1678. <https://doi.org/10.1021/es0488737>
35. Diaz-Sanchez D, Tsien A, Fleming J, Saxon A. Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human in vivo nasal ragweed-specific IgE and skews cytokine production to a T helper call 2-type pattern. *J Immunol.* 1997;158(5):2406-13.
36. Katz DSW, Batterman SA. Urban-scale variation in pollen concentrations: a single station is insufficient to characterize daily exposure. *Aerobiologia (Bologna).* 2020;36(3):417-431. <https://doi.org/10.1007/s10453-020-09641-z>
37. Katelaris CH, Burke TV, Byth K. Spatial variability in the pollen count in Sydney, Australia: can one sampling site accurately reflect the pollen count for a region? *Ann Allergy Asthma Immunol.* 2004;93(2):131-136. [https://doi.org/10.1016/S1081-1206\(10\)61464-0](https://doi.org/10.1016/S1081-1206(10)61464-0)
38. Bergman KC, Berger M, Klimek L, et al. Nonpharmacological measures to prevent allergic symptoms in pollen allergy: a critical review. *Allergol Select.* 2021;5:349-360. <https://doi.org/10.5414/ALX02294E>